Fundraising FoxRA Capital — 2019 Investments
10 investments dated 2019 · listed companies and verified rows first · show all
Arcutis is a biopharmaceutical company focused on dermatology, developing treatments for immune-mediated skin diseases such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis, and scalp psoriasis.
BiotechHealthtechMedical DevicesWestlake Village, US
Todd Franklin Watanabe(Executive Officer, Director)Alexander Asam(Director)Ricky Sun(Director)
BoardPatrick Heron(Director)inDaniel Estes(Director)inJonathan Silverstein(Director)
Co-investorsBain Capital Life SciencesFrazier Life Sciences
Boundless Bio develops precision oncology medicines targeting ecDNA-amplified cancers, specifically creating a new category of ecDNA-directed therapies for patients with oncogenic alterations.
BiotechMedical DevicesLa Jolla, US
Zachary D. Hornby(Executive Officer, Director)inRobert Doebele(Chief Medical Officer)inChristian Hassig(Chief Scientific Officer)Jessica Oien(Chief Legal Officer and Corporate Secretary)in
BoardBenjamin Cravatt, Ph.D.(Director)Kristina Burow(Director)in
Co-investorsARCH Venture PartnersNextech InvestWellington ManagementAlexandriaCity Hill VenturesSectoral Asset Management+3 more
Imara is a clinical-stage biopharmaceutical company developing small molecule therapeutics for unmet medical needs, currently advancing ELVN-001, a selective kinase inhibitor designed to treat chronic myeloid leukemia by targeting the BCR-ABL gene fusion.
BiotechCambridge, US
James G. McArthur(Executive Officer, Director)Christoph M. Adams(Executive Officer, Director)Richard Fair(President, Chief Executive Officer, Director)
BoardSara Nayeem(Director)Barbara Dalton(Director)David Mott(Director)
Co-investorsBay City CapitalNew Enterprise Associates (NEA)Pfizer Venture InvestmentsAlexandriaArix BioscienceJMI Equity+3 more
Nkarta is a biotech company developing allogeneic CAR NK cell therapies for autoimmune diseases, aiming to offer safer and more accessible alternatives to autologous CAR-T treatments.
BiotechHealthtechSouth San Francisco, US
Paul Hastings(Executive Officer, Director)inPaul H.inMatthew Plunkett(Executive Officer)in
BoardMichael Dybbs(Director)Jill Carroll(Director)inTiba Aynechi(Director)in
Co-investorsNew Enterprise Associates (NEA)Samsara BioCapitalSR One Capital ManagementAmgen VenturesLogosNorwest Venture Partners+1 more
Diamond Therapeutics is a preclinical biotechnology company developing drug treatments for psychiatric and neurological disorders, with a focus on the pharmacology and therapeutic use of psychedelic compounds.
BiotechHealthtechMental HealthToronto, CA
Judy Blumstock(Chief Executive Officer, Founder, Director)inMichael B. McDonnell(Chief Medical Officer)Grant McCutcheon(Chief Financial Officer)in
Co-investorsJLSNoeticPalo Santo VCNew Enterprise Associates (NEA)Nextech Invest
BiotechSan Diego, US
Stephen W. Kaldor(Executive Officer, Director, Promoter)Eric Murphy(Executive Officer, Director)
BoardBret Zbar(Director)Carl Gordon(Director)Michael Rome(Director)in
Co-investorsForesite CapitalNextech InvestViking GlobalJanus Henderson InvestorsVenrock Healthcare Capital PartnersViking Global Investors
Satsuma Pharmaceuticals develops therapeutics for the acute treatment of migraine, including an approved dihydroergotamine nasal powder product (Atzumi/STS101).
BiotechHealthtechMedical DevicesSouth San Francisco, US
John Kollins(Executive Officer, Director)Tadayoshi Iwashima(Executive Officer)Thomas B. King(President and Board Director)inRob Janosky(Chief Commercial Officer)Tom O'Neil(Chief Financial Officer)inDavid Prichard(Chief Operating Officer)
Co-investorsOUP (Osage University Partners)Vivo CapitalWellington ManagementLumira VenturesRed Tree VentureSBI Investment
Tasso develops diagnostic testing devices and platforms for home use, enabling patients to perform health monitoring and inform clinical decisions outside traditional healthcare settings.
Digital HealthHealthtechMedical DevicesSeattle, US
Ben Casavant(Co-Founder and Chief Executive Officer)inErwin Berthier(Co-Founder and Chief Technology Officer)inAlan Levy(Director)
BoardElizabeth Hambrecht(Director)Paul Conley(Director)in
Co-investorsForesite CapitalJ2 VenturesMerck Global Health Innovation FundMSD Global Health Innovation FundOMX VenturesTechstars+3 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Aerovate TherapeuticsAset Therapeutics
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.